PART II. OTHER

OPTIMIZED UPSTREAM THERAPY FOR MANAGING PATIENTS WITH POSTINFARCTION CARDIOSCLEROSIS ASSOCIATED WITH HYPERURICEMIA

ZOPTYMALIZOWANA TERAPIA WSTĘPNA W CELU LECzenIA PACJENTÓW Z TWARDZINĄ SERCA ZWIĄZANĄ Z HIPERURYKEMIĄ

Sofiya Lypovetska1(A,B,C,D), Olena Prokopovich1(B,F), Mykola Shved1(A,E), Tetyana Boyko1(D,F)

1I. Horbachevsky Ternopil State Medical University, Ukraine

Summary

Background. The recent epidemiological studies have shown that serum uric acid (SUA) is a risk factor for cardiovascular diseases and a negative prognostic marker for mortality in subjects with pre-existing heart failure.

Material and methods. 147 patients, (59.2±0.8) years old, with postinfarction cardiosclerosis were included in this study. An evaluation of cardiohemodynamics, heart rhythm disturbances, lipid and purine metabolism, and systemic inflammation was performed before treatment and six months afterwards.

Results. An elevated SUA level was associated with the progression of postinfarction heart remodeling. Heterogeneity of ventricular repolarization, decrease of heart rate variability, as well as high grade premature ventricular complexes were observed in these patients. Complex treatment with eprosartan provided a significant regress of left ventricle hypertrophy, achievement of target blood pressure levels, complete recovery from ventricular tachycardia, prevention of new-onset of atrial fibrillation. The use of fenofibrate resulted in reducing of total cholesterol, triglycerides, low density lipoproteins, SUA and main markers of systemic inflammation as well as an increase high density lipoproteins.

Conclusions. The use of eprosartan and fenofibrate is an optimized upstream strategy for managing patients with postinfarction cardiosclerosis associated with hyperuricemia.

Keywords: postinfarction cardiosclerosis, hyperuricemia, inflammatory biomarkers

Słowa kluczowe: twardzina serca, hiperurykemia, biomarkery zapalne

Introduction

The role of serum uric acid (SUA) in the process of atherosclerosis and atherothrombosis is controversial. The recent epidemiological studies (NHANES I, Honolulu Heart study, the MONICA/CORA Study Cohort, PIUMA, SHEP, Syst-China, etc.) have shown that SUA may be a risk factor for cardiovascular diseases and a negative prognostic
marker for mortality in subjects with pre-existing heart failure [1,2,3,4,5,6]. According to the WHO experts’ recommendations, hyperuricemia is considered to be a component of metabolic syndrome [7,8,9,10,11,12].

However, the influence of hyperuricemia on the increase of post-infarction remodelling of the heart, the onset of arrhythmia or development of heart failure is not completely defined. The same pertains to the efficiency of hypouricemic drugs [13]. The LIFE study showed that a decrease in SUA was associated with better long-term results in patients who were treated with losartan, as compared to those who took atenolol [14]. In addition, a meta-analysis of seven randomized trials (TRACE, SOLVD, ValHeFT, CHARM, etc.) demonstrated that treatment with ACE inhibitors and angiotensin-receptor blockers reduced the risk of atrial fibrillation (AF) and sudden cardiac death due to left ventricular hypertrophy regression, provided protection against atrial enlargement and supraventricular arrhythmias, as well as affected endothelial function, risk biomarkers and vascular remodelling [15,16,17].

Also, an important prerequisite for reducing of arrhythmogenesis is a complex correction of atherogenesis. The presence of combined dyslipidemia, hypertriglyceridemia combined with hyperuricemia in patients after myocardial infarction demands additional assignments of fibrates [18,19,20].

Objective: The study was undertaken to find out disturbances in cardiohaemodynamics, heart rhythm, lipid, purine metabolism and systemic inflammation, as well as the efficiency of upstream therapeutic strategies with eprosartan and fenofibrate in patients with postinfarction cardiosclerosis, associated with hyperuricemia.

Material and methods

The study was conducted in the Cardiology Department of Ternopil University hospital and involved 147 patients with post-infarction cardiosclerosis (106 men and 41 women) aged (59.2 ± 8.8) years. The diagnosis was established by confirming the presence of myocardial infarction in anamnesis, clinical signs, ECG, including retrospective analysis, Echocardiography and the absence of myocardial necrosis markers.

The exclusion criteria included: acute coronary syndrome within the last 3 months, postinfarction cardiosclerosis within the first 6 months, severe renal and hepatic failure, exacerbation of chronic and acute inflammatory diseases, secondary hypertension, hemodynamically significant valvular heart disease, heart failure IV functional class.

Depending on the presence of hyperuricemia, all patients were preliminary stratified into 2 groups. Group I included 106 patients with postinfarction cardiosclerosis, combined with hyperuricemia (0.59 ± 0.06) mmol/l and group II – 41 patients with normal level of SUA (0.32 ± 0.05) mmol/l. A comparative evaluation of atherosclerosis risk factors, medical history, disorders of cardiac hemodynamics, heart rhythm disturbances, lipid metabolism, markers of systemic inflammation was performed.

In order to determine the efficiency of upstream therapeutic strategies of postinfarction cardiosclerosis, associated with hyperuricemia, the patients were divided into 4 groups: group I included 30 patients who underwent standard treatment according to the Guidelines of European Cardiology Association, group II – 25 patients who instead of ACE inhibitors took eprosartan 600 mg once daily, group III – 25 patients who, in addition to the standard treatment, were prescribed with fenofibrate 200 mg daily, group IV – 26 patients who took eprosartan and fenofibrate. Patients of all groups were comparable in age, sex, degree of metabolic disorders and the level of postinfarction changes. All were prescribed with fenofibrate 200 mg daily, group IV – 26 patients who took eprosartan and fenofibrate. Patients of all groups were comparable in age, sex, degree of metabolic disorders and the level of postinfarction changes.

The study was undertaken to find out disturbances in cardiohaemodynamics, heart rhythm, lipid, purine metabolism and systemic inflammation, as well as the efficiency of upstream therapeutic strategies with eprosartan and fenofibrate in patients with postinfarction cardiosclerosis, associated with hyperuricemia.

Optimized upstream therapy...
Results and discussion

An important step of clinical examination of patients with postinfarction car-diosclerosis included a comparative analysis of risk factors and their stratification dependent on the presence of hyperuricemia. Such modified atherosclerosis risk factors as dyslipidemia, obesity, diabetes mellitus, arterial hypertension (AH) were definitely more often observed in patients with hyperuricemia (p<0.01). According to the IDF criteria, metabolic syndrome was identified 8.3 times more frequently in patients with elevated SUA level than with normal (60.5% vs. 7.3%). Table 1 presents correlation of SUA level with risk factors of atherosclerosis.

Table 1. Correlation of serum uric acid with risk factors of atherosclerosis

| Index                        | r    | p    |
|------------------------------|------|------|
| Age                          | 0.09 | > 0.05 |
| Body mass index, kg/m²       | 0.36 | < 0.01 |
| Waist circumference, sm      | 0.50 | < 0.01 |
| Index waist/hip              | 0.14 | > 0.05 |
| Systolic BP, mm Hg           | 0.25 | < 0.01 |
| Diastolic BP, mm Hg          | 0.09 | > 0.05 |
| Hyperglycemia, mmol/l        | 0.22 | < 0.05 |
| TC, mmol/l                   | 0.40 | < 0.01 |
| HDL, mmol/l                  | -0.46| < 0.01 |
| TG, mmol/l                   | 0.47 | < 0.01 |
| LDL, mmol/l                  | 0.40 | < 0.01 |
| VLDL, mmol/l                 | 0.50 | < 0.01 |

Patients with hyperuricemia compared with patients with normal level of SUA, had Q-wave myocardial infarction in anamnesis (61.3% vs. 17.1%), mostly anterior localition (53.8% vs. 28.6%). Pronounced hemodynamic impairments and occurrence of congestive heart failure occurred 4.6 times more often in patients with hyperuricemia.

The patients with an increased SUA compared to those with normouricemia, had a significantly increased end-diastolic dimension of LV (LV EDD) by 11.6%, thickness of the interventricular septum (IVST) – by 22.9%, the thickness of posterior wall (PWT) by 20.3%, MM LV – 37.7%, mass index of left ventricular (LVMI) – 33.3% (p<0.01). It was established that with increasing SUA, LVMI was also higher (Fig. 1).

Figure 1. A linear relationship of uric acid with myocardial mass index of left ventricle in patients with postinfarction car-diosclerosis
The analysis of LV remodeling in patients with hyperuricemia compared to patients with normouricemia showed that concentric (56.6% vs 26.8%) and eccentric (40.6% vs 31.7%) hypertrophy dominated.

The patients with hyperuricemia compared to patients with normouricemia more often showed diastolic dysfunction of LV (85.8% vs. 36.6%): relaxation type (19.8% vs. 9.7%), pseudonormal type (67.0% vs. 26.8%). Restrictive type was identified only in patients with elevated SUA (13.2%). Systolic dysfunction was diagnosed in 15 (14.2%) patients with hyperuricemia and 5 (12.2%) – with normouricemia. A positive significant correlation of SUA with the size of the left atrium (LA), right ventricle, IVST, EDD LV, MM LV, IMM LV (r=0.30-0.49, p<0.01), and PWT LV (r=0.22, p<0.05) and indices of diastolic function: E, DTE (r=0.26-0.61, p<0.01), E/A (r=0.21, p<0.05) was found.

An analysis of arrhythmias showed no significant difference between the frequency of supraventricular arrhythmias (AF, supraventricular extrasystoles (SES)) in patients with high and normal level of SUA. The differences was found among ventricular arrhythmias: ventricular extrasystoles (VES) II − class IV by B. Lown- M. Wolf and conduction disturbances in His-Purkinje system were recorded significantly more often (2.5 times) in patients with hyperuricemia.

Patients with high SUA level had significantly higher (42.8 ms) Q-Td, compared with patients with normouricemia (p<0.05). The assessment of day rhythms of Q-T showed that duration of Q-Tc was higher at night than during the day by 20.8 ms, and Q-Td – 20.0 ms. A correlation between the value of Q-Tc and episodes of unstable ventricular tachycardia was found (r=0.42, p<0.05).

The assessment of HRV in patients with postinfarction cardiosclerosis showed that all time indices were reduced, regardless of the presence of hyperuricemia. However, in patients with large myocardial damage, time indices were even smaller and critically low – in patients with LV aneurysm, complicated by congestive heart failure (p<0.01). With the deterioration of the clinical conditions, an average heart rate was significantly increased, directly indicated the increase of sympathetic tone. However, the increase of sympathoadrenal influences did not result in an increase of the LF spectrum, but was accompanied by its decline.

The lipid profile of patients with hyperuricemia was characterized by significantly higher indices of TC by 20.9%, TG – by 38.1%, LDL – by 31.8% and lower HDL – 32.8% (p<0.01) in comparison with patients with normal SUA level. Combined dyslipidemia (67.9% vs. 2.4%) and hypertrigliceridemia (6.6% vs. 2.4%) were dominated among them.

However, patients with hyperuricemia had significantly increased markers of systemic inflammation, particularly CRP – by 71.4%, IL-1 – 49.9%, TNF-α – 76.2% (p<0.01) compared to patients with normouricemia. A correlation was established between increased levels of SUA and CRP (r=0.7, p<0.01), and TNF-α (r=0.8, p<0.01), and IL-1 (r=0.7, p<0.01). In addition, it was shown that with increasing of SUA, increasing of CRP, IL-1, TNF-α was observed, which confirms the role of hyperuricemia in systemic inflammatory response (Fig. 2, 3, 4).

Figure 2. A linear relationship of uric acid with C-reactive protein in patients with postinfarction cardiosclerosis
The standard treatment contributed to the improvement in 46.7% patients of group I, mainly due to the reduction of heart failure. However, the target BP levels were achieved only in 36.8% of the patients. After 6 months, a significant decrease of LV MM by 10.9 g and LV MI by 9.5 g/m² (p<0.05) were defined, testifying reduction of LV hypertrophy (IVST on 3.5% and PWT LV on 5.6% (p<0.05)). However, the relative wall thickness did not change, which proved the prevalence of concentric hypertrophy in these patients. Also, the ejection fraction (EF) LV did not changed significantly.

The results of spectral analysis of HRV showed that most patients had an increased sympathetic tone. In 53.3% patients, SDNN remained at the level less than 100 ms. In addition, they had VES of high grades, no significant dynamics in the duration Q-T interval.
The standard treatment provided a reduction of most atherogenic fractions of lipids, except TG and SUA, but did not lead to sufficient growth of HDL. The presence of hypertriglyceridemia and hyperuricemia are negative factors that do not provide adequate balance in the metabolism of purines and lipids.

A 6-month treatment with eprosartan contributed to the clinical improvement in 80.0% patients of group II due to reduction of heart failure and adequate treatment of hypertension. Target BP was achieved in 60.0% of patients. LV MM was decreased by 15.6 g, MM LV – 10.5 g/m² and LVEF was increased by 3.7% (p<0.01), decreasing of E by 13.0 sm/s (14.1%) and the growth of A by 18.1 sm/s (23.6%) (p<0.01) were detected. The ratio E/A was decreased by 0.32 units (26.4%) (p<0.01), and DecF was increased by 3.5 ms (1.8%) (p<0.05). All these changes indicated an improvement in diastolic LV filling and, consequently, a correction of diastolic dysfunction.

An average heart rate was decreased by 13.1% in the afternoon and 19.7% at night, which was accompanied by an increased circadian index. The total number of VES was decreased by 73.7% (p<0.01), and the frequency of the episodes of the paired VES – 84.4% (p<0.05), SES – by 70.6% (p<0.01), and paired SES – by 70.2% (p<0.01), and group – by 41.4% (p<0.05). At the same time, we observed a significantly increased SDNN on 12.5%, SDNNidx – 22.1%, SDANN – 10.6%, pNN50% – 24.0%, nHF – 18.0% and reduction of VLF – by 21.8%, LF – 15.2% (p<0.01).

The positive dynamics in the duration of Q-T interval was observed, in particular the average Q-Tc duration was significantly decreased by 2.6 ms (p<0.05), maximum – by 8.4 ms (p<0.01), and average QTc – 3.0 ms (p<0.05) and maximum – by 11.2 ms, QTd – by 15.1 ms (p<0.01).

The dynamics of clinical manifestations of the disease, indices of cardiac hemodynamics, arrhythmias, BP in patients of group III, whose treatment included fenofibrate, were similar as in the patients of group I. However, there was observed a significant improvement of lipid and purine metabolism: the contents of serum CH decreased by 26.6%, TG – 39.4%, LDL – 38.4%, VLDL – 39.6%, while HDL increased by 30.1% (p<0.01). The content of CRP decreased by 76.3%, IL-1 – 46.4%, TNF-α – 56.3% (p<0.01). The correlation analysis showed no relationship between the decrease of lipid atherogenic fractions and CRP (r = 0.08, p = 0.5), TNF-α (r = 0.015, p = 0.2), IL-1 (r = 0.18, p = 0.2), indicating independence of lipid lowering and anti-inflammatory effects of fenofibrate.

The inclusion of eprosartan and fenofibrate in the treatment contributed to the improvement of the clinical status in 88.5% of the subjects of group IV due to reduction of arrhythmias, heart failure and control of hypertension. Target BP levels were achieved in 85.7% patients. The most prominent reduction of LV hypertrophy (14.3 g/m² (6.6%)) and significant (p<0.05) decrease in the size of LA (8.0%) was achieved in group IV. A significant increase of LVEF by 6.2% (p<0.01) was observed.

The decrease in the average day heart rate by 11.3% and 12.2% at night were found, which was accompanied by normalization of the circadian index. The total number of VES was decreased by 66.4% (p<0.01), and complete elimination of episodes of ventricular tachycardia was achieved, polymorphic, early and paired extrasystoles were decreased by 94.1%. In addition, the total number of SES were reduced by 74.2% (p<0.01), and pair – by 67.2% (p<0.01), and group – 50.9% (p<0.05). During the follow-up, new paroxysms of atrial fibrillation and supraventricular tachycardia in patients of this group were not detected. The average duration of Q-T interval was significantly decreased by 9.3 ms (p<0.05), the maximum Q-Tc – 16.5 ms (p<0.01), and Q-Td – 17.0 ms (p<0.01). At the same time, HRV was significantly increased: SDNN – by 19.7%, SDANN – 29.1%, pNN50% – 26.9% (p<0.01), and RMSSD – 18.8% (p<0.05). VLF and LF were decreased by 29.6% and 23.2% respectively, HF and nHF were increased on 14.8% and 25.1% (p<0.01).

Sustained lipid lowering, hypouricemic and pleiotropic effects were achieved due to the treatment in group IV: the level of TC was decreased by 21.1%, TG – 44.2%, LDL – 30.1%, VLDL – 43.8%, SUA – 37.5%, the level of HDL was increased by 30.7% (p<0.01). A significant reduction of CRP by 71.2%, TNF-α – 69.0%, IL-1 – 47.1% (p<0.01) were found.

Summarizing the obtained results, optimized upstream treatment with eprosartan and fenofibrate effectively influence the process of systemic atherogenesis, which is the pathogenic background of coronary artery disease, correcting the combined dyslipidemia, hyperuricemia, reducing of systemic inflammation. Long-term blockade of the renin-angiotensin and sympathetic-adrenal systems contributes to the reduction of pathological post-infarction remodelling, arrhythmogenesis and control of arterial hypertension.

Conclusions

1. Hyperuricemia was associated with intensive post-infarction heart remodelling, manifested in an increase of myocardial mass of left ventricle ((220.9±6.9) g/m²) and violation of its geometry: concentric (56.6%) and eccentric (40.6%) hypertrophy with diastolic dysfunction (relaxation type – 19.8%, pseudonormal – 67.0% and restrictive – 13.2%). Between elevated uric acid levels, parameters of intracardiac hemodynamics and diastolic function significant correlation relationship were found (r = 0.4-0.6, p<0.01).

2. Patients with postinfarction cardiosclerosis, associated with hyperuricemia, were characterized by heterogeneity of ventricular repolarisation (dispersion of Q-T more than 70 ms), total vegetative imbalance with a predominance of sympathetic tone and reduction of time parameters of heart rate variability (SDNN less than 100
ms). At the same time, they had a significantly (2.5 times) more often recorded ventricular extrasystoles class II–IV by B. Lown-M. Wolf and conduction disturbances in the system. His-Purkinje, compared with patients with normouricaemia.

3. Patients with postinfarction cardiosclerosis, associated with hyperuricaemia, in 70.9% cases had combined dyslipidemia with hypertriglyceridemia, low levels of high-density lipoproteins, combined with an increased activity of markers of systemic inflammation. The close correlation was established between increased levels of uric acid and C-reactive protein (r=0.7, p<0.01), tumor necrosis factor α (r=0.8, p<0.01), and interleukin -1 (r=0.7, p<0.01).

4. Eprosartan, included in the standard medical treatment, contributed to a significant reduction of left ventricular hypertrophy (myocardial mass index decreased by 14.3 g/m²) and an increase of ejection fraction from (46.2±1.2) to (52.4±1.1)%. Circadian index, heart rate were normalized, the overall number of ventricular extrasystoles were decreased by 66.4%, episodes of ventricular tachycardia, polymorphic extrasystoles were eliminated, the length of Q-Tc interval and Q-T dispersion were decreased by 21.1% and heart rate variability was increased. Target levels of blood pressure were achieved in 85.7% patients.

5. Fenofibrate, included in in the standard medical treatment, provided sustainable hypouremic, lipid-lowering and pleiotropic effects, which were manifested by lowering the total cholesterol by 21.1%, triglycerides – 44.2%, low-density lipoproteins − 30.1%, serum uric acid – 37.5%, C-reactive protein – 71.2%, of tumor necrosis factor α – 69.0%, interleukin I − 47.1% and an increase of high density lipoproteins - on 30.7%.

References:

1. Capuano V, Marchese F, Capuano R, Torre S, Iannone AG, Capuano E, et al. Hyperuricemia as an independent risk factor for major cardiovascular events: a 10-year cohort study from Southern Italy. J Cardiovasc Med (Hagerstown). 2017 Mar; 18(3): 159-164. doi: 10.2459/JCM.0000000000000347.

2. Dutta A, Henley W, Pilling LC, Wallace RB, Melzer D. Uric acid measurement improves prediction of cardiovascular mortality in later life. J Am Geriatr Soc. 2013; 61: 319–326.

3. Khan A, Mohammad HS, Khan S, Shamin U, Arshad S. Serum Uric Acid level in the severity of Congestive Heart Failure (CHF). Pak J Med Sci. 2017 Mar-Apr; 33(2): 330-334. doi: 10.12669/pjms.332.11779.

4. Min L, Xiaolan H, Yingli F, Kun L, Xiaowe Z, Wensheng H, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Scientific report. 2016; 6: 9520; doi: 10.1038/srep19520.

5. Lypovetska S. Role of uric acid in progression of heart remodeling in patients after myocardial infarction: liaison between metabolic profile and subclinical inflammation. European Journal of Heart Failure. 2017; 19 (Issue Supplement S1): 133.

6. Pascual-Figal DA, Hurtado-Martinez JA, Redondo B. Hyperuricemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail. 2006; 9: 518-524.

7. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007; 49: 298-303.

8. Kuwabara M, Niwa K, Hisatome I. Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases: Five-Year Japanese Cohort Study. Hypertension. 2017; Jun; 69(6): 1036-1044. doi: 10.1161/HYPERTENSIONAHA.116.08998. Epub 2017 Apr 10.

9. Mazza A, Lenti S, Schiavon L, Del Monte A, Danyelle M. Townsend D, Ramazzina E. Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population. Biomed Pharmacother. 2017; 86: 590-594.

10. Savarese G, Ferri C, Trimarco B. Changes in serum uric acid levels and cardiovascular events: a meta-analysis. Nutr Metab Cardiovasc Dis. 2013; 23: 707–714.

11. Skak-Nielsen H, Torp-Pedersen C, Finer N, Caterson I, Van Gaal L, Philip T James. Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. PLoS One. 2013, 8: e59121

12. Viazzi F, Piscitelli P, Giorda C, Ceriello A, Genovesi S, Russo G, et al. Metabolic syndrome, serum uric acid and renal risk in patients with T2D. PLoS One. 2017 Apr 19; 12(4): e0176058. doi: 10.1371/journal.pone.0176058. eCollection 2017.

13. Bove M, Cicero AF, Veronesi M. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. Vasc Health Risk Manag. 2017; 13: 23-28.

14. Hoiegen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65: 1041–1049.

15. Anand K, Mooss An, Hee TT. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J. 2006; 152 (2): 217-222.
16. Maharani N, Kuwabara M, Hisatome I. Hyperuricemia and Atrial Fibrillation. Int Heart J. 2016 Jul 27; 57(4): 395-9. doi: 10.1536/ihj.16-192. Epub 2016 Jul 11. Review

17. Petrella RJ, Gill DP, Berrou JP. Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients with diabetes: results of the POWER survey, 2015 Mar 24; 8: 173-80. doi: 10.2147/DMSO.S79221.

18. Guang-zhong Liu, Ting-ting Hou, Yue Yuan, Peng-zhou Hang, Jing-jing Zhao, Li Sun, et al. Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-α/sirtuin 1/PGC-1α pathway. Br J Pharmacol. 2016 Mar; 173(6): 1095–1109.

19. Petersen TS, Madsen TV, Jespersen JB, Larsen A, Schmidt EB, Christensen JH. Uric acid in patients with angiographically documented coronary heart disease. Acta Cardiol. 2006; 61(5): 525-529.

20. Spiga R, Marini MA, Mancuso E, Di Fatta C, Fuoco A, Perticone F, et al. Uric Acid Is Associated With Inflammatory Biomarkers and Induces Inflammation Via Activating the NF-κB Signaling Pathway in HepG2 Cells. Arterioscler Thromb Vasc Biol. 2017 Apr 13. pii: ATVBAHA.117.309128. doi: 10.1161/ATVBAHA.117.309128

21. Storhaug H, Norvik J, Toft I, O Eriksen B, Lochen ML, Zykova S, et al. Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from The Tromso Study. BMC Cardiovasc Disord. 2013,13: 115.